[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1990

Oral Cyclosporine in the Treatment of Inflammatory and Noninflammatory DermatosesA Clinical and Immunopathologic Analysis

Author Affiliations

From the Departments of Dermatology (Drs Gupta, Ellis, Nickoloff, Goldfarb, Ho, Griffiths, Cooper, and Voorhees), Pathology (Dr Nickoloff), and Internal Medicine (Dr Rocher), the University of Michigan Medical School, Ann Arbor. Dr Gupta is now with the National Cancer Institute, National Institutes of Health, Bethesda, Md.

Arch Dermatol. 1990;126(3):339-350. doi:10.1001/archderm.1990.01670270071012
Abstract

• Cyclosporine is known to be effective in the treatment of psoriasis. In this study, we have used oral cyclosporine (6 mg/kg per day) given for 5 to 30 weeks to 24 patients for the treatment of 12 different dermatoses. Patients with the following diseases demonstrated a marked response or total clearing: 1 patient each with pyoderma gangrenosum, pityriasis lichenoides chronica, and psoriasis of the acrodermatitis continua of Hallopeau type. Moderate to marked response occurred in both patients with epidermolysis bullosa acquisita and the patient with hidradenitis suppurativa. Minimal to moderate responses were obtained in both patients with granuloma annulare, 1 of 2 with acrodermatitis continua of Hallopeau, both patients with Darier's disease, and 1 of 6 patients with vitiligo. Little or no response was noted in both patients with sarcoidosis, all 3 patients with pityriasis rubra pilaris, 5 of 6 patients with vitiligo, 1 patient with pemphigus foliaceous, and 1 with pemphigus vulgaris. Clinical side effects were mild and transient and included dysesthesia, fatigue, hypertrichosis, nausea, and flushing. The most frequent clinically significant abnormalities were hypertension and renal dysfunction, with all factors normalizing within 1 month of discontinuation of cyclosporine therapy.

(Arch Dermatol. 1990;126:339-350)

×